Stephen Eeden to Gonadotropin-Releasing Hormone
This is a "connection" page, showing publications Stephen Eeden has written about Gonadotropin-Releasing Hormone.
Connection Strength
0.609
-
Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer. J Urol. 2015 Jun; 193(6):1956-62.
Score: 0.249
-
Efficacy of intermittent androgen deprivation therapy vs conventional continuous androgen deprivation therapy for advanced prostate cancer: a meta-analysis. Urology. 2013 Aug; 82(2):327-33.
Score: 0.226
-
Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study. Br J Cancer. 2017 Oct 10; 117(8):1233-1240.
Score: 0.075
-
Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer. J Clin Oncol. 2014 May 01; 32(13):1324-30.
Score: 0.059